Tumor Characteristics in Patients With Paraneoplastic Neurological Syndromes (PNS)

• Conditions: Paraneoplastic Syndromes; Immune System and Related Disorders; Neurologic Disorder; Tumor Genetics; Cancer

• Registration Number: NCT03963700
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

Paraneoplastic neurological syndromes (PNS) are immune-mediated complications of cancer that can affect any part of the central or peripheral nervous system.

PNS occurs at the intersection between immune system and the tumor, where a combination of genetical and environmental factors may play a role.

Mechanisms leading to immune tolerance breakdown and autoimmunity in PNS remain largely unknown, and this reflects in an unsatisfactory repertoire of treatments available. Moreover, a better understanding of the biological mechanisms underlying PNS would allow a more precise identification of the modalities that permit PNS patients to have a better oncological prognosis than cancer patient without PNS, with obvious repercussions in clinical oncology.

To this effect, an extremely innovative approach involves directly exploring the tumoral tissue of patients suffering from specific PNS via genomic and transcriptomic analysis.

The study team hypothesizes that antigen ectopic expression by tumour cells may contribute to the generation of PNS.

In the present study, the investigators will analyze the salient features of tumors associated with PNS, namely the histological and immune cells infiltrate characteristics, their transcriptomic profile, and mutational status of involved antigens.

Detailed Description

Not available

Study Timeline

• Study Start: 2019-02-01
• Study First Submitted: 2019-04-26
• Status Verified: 2019-05
• Study First Submitted QC: 2019-05-23
• Study First Posted: 2019-05-28
• Last Update Submitted: 2019-05-28
• Last Update Posted: 2019-05-30
• Primary Completion: 2022-01-01
• Study Completion: 2022-01-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 980

Inclusion Criteria

• presence of well characterized antibodies in serum or cerebrospinal fluid;
• histologically proven cancer with available tumour sample;
• Paraneoplastic neurological syndrome (PNS) diagnosis according to the international guidelines;
• Age: at least 18 years old.

Read More

Exclusion Criteria

• Absence of complete clinicopathological data

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Proportion of mutations in cancer genes coding for onconeural proteins and inflammatory response mediators.	36 months	Genetic alterations in tumors associated with Paraneoplastic neurological syndromes (PNS)

Secondary Outcome Measures

Name	Time	Method
Proportion of different immune cells in the tumor's immune infiltrate	36 months	Histological immune infiltrate characteristics

Trial Locations

Locations (1)

Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes; 🇫🇷 Lyon, France